DNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ginkgo Bioworks Holdings Inc (DNA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock has shown mixed signals with a recent decline in revenue and ongoing challenges in its business segments. While there are some positive developments, such as improved net income and cash reserves, the lack of strong growth trends and the absence of significant trading signals suggest it is better to hold off on buying for now.
The MACD is positive and expanding, which is a bullish signal. However, the RSI is neutral at 61.842, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 8.773) and below its pivot point (9.182), suggesting limited upward momentum in the short term.
The company has improved its net income year-over-year, reducing its losses significantly. It also holds $423 million in cash and cash equivalents, providing financial stability. The divestiture of the biosecurity business could allow Ginkgo to focus on high-growth areas like autonomous labs and AI-driven robotics.
The cell engineering segment also saw a 26% decline in revenue. Gross margins have dropped, and the company anticipates continued challenges in
Analysts have lowered their price targets, reflecting cautious sentiment.
In Q4 2025, the company reported a net loss of $312.8 million, an improvement from $547 million in Q4 2024. Total revenue for the quarter was $33 million, down 24% year-over-year. The cell engineering segment generated $26 million, down 26% year-over-year. As of December 31, 2025, the company held $423 million in cash and cash equivalents.
Analysts have maintained a Buy rating but significantly lowered the price target from $14 to $12, reflecting cautious optimism. They highlight the importance of 2026 guidance updates for sector recovery and favor stocks with clear multi-year growth frameworks.
